Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Scott Manetz"'
Autor:
Mariam Ibrahim, Ian Wallace, Saba Ghazvini, Scott Manetz, Ruth Cordoba-Rodriguez, Sajal M. Patel
Publikováno v:
Journal of Pharmaceutical Sciences. 112:1341-1344
Autor:
Philip M. Hemken, Nicolette M. Jeanblanc, Tracey Rae, Susan E. Brophy, Maria J. Datwyler, Ying Xu, T. Scott Manetz, Inna Vainshtein, Meina Liang, Xiaodong Xiao, Partha S. Chowdhury, Chien-ying Chang, Katie Streicher, Lydia Greenlees, Koustubh Ranade, Gerard J. Davis
Publikováno v:
Practical Laboratory Medicine, Vol 9, Iss , Pp 58-68 (2017)
Background: Dipeptidyl peptidase-4 (DPP-4) may be a suitable biomarker to identify people with severe asthma who have greater activation of the interleukin-13 (IL-13) pathway and may therefore benefit from IL-13-targeted treatments. We report the ana
Externí odkaz:
https://doaj.org/article/b5d2f2e9efc14bc1853381f654d6d33b
Autor:
Graham Paul, Stuart W. Naylor, Nicholas P. Macri, Scott Manetz, Richard Haworth, A. Peter Hall, David Jones, Thierry Flandre, Jeffrey S. Tepper, Michela Gregori, Annick Cauvin, Molly H. Boyle, Sydney Mukaratirwa, Alison Wolfreys, Renaud Fleurance, Inge Tarnow, Kristen J. Nikula, Alessandro Piaia, Mark Price, Ian Robinson, Andrew Allen, Tom Gelzleichter, Mark C Freke, Karyn Colman, Andreas M Hohlbaum, Maurice G Cary
Publikováno v:
Toxicologic Pathology. 49:235-260
The inhalation route is a relatively novel drug delivery route for biotherapeutics and, as a result, there is a paucity of published data and experience within the toxicology/pathology community. In recent years, findings arising in toxicology studie
Publikováno v:
Immunology and Allergy Clinics of North America. 38:611-628
Periostin and dipeptidyl peptidase-4 (DPP-4) are proteins induced by type 2 cytokines interleukin (IL)-4 and IL-13 and show increased expression in asthma and diseases with type 2 inflammation, including atopic dermatitis and chronic rhinosinusitis.
Autor:
Ian Robinson, Simon Moore, Jo Kilgour, Sidney Mukaratirwa, Mark Price, David Jones, Annick Cauvin, Carsten Krantz, Mark C Freke, Andrew Allen, Alison Wolfreys, Jeffrey S Tepper, Scott Manetz, Sherri Dudal, George Karantabias
Publikováno v:
Toxicologic pathology. 49(2)
The inhaled route is still a relatively novel route for delivering biologics and poses additional challenges to those encountered with inhaled small molecules, further complicating the design and interpretation of toxicology studies. A working group
Autor:
Lauren Wetzler, Tom Brown, Amy D. Klion, Irina Maric, Scott Manetz, Fei Li Kuang, Elizabeth Battisto
Publikováno v:
J Allergy Clin Immunol Pract
Publikováno v:
International Journal of Toxicology. 32:327-335
A recombinant vaccine (rF1V) is being developed to protect adults 18 to 55 years of age from fatal pneumonic plague caused by aerosolized Yersinia pestis. A comprehensive series of studies was conducted to evaluate the general toxicity and local reac
Autor:
Gerard J. Davis, Reena Varkey, Ethan Grant, Meina Liang, Susan Brophy, Lydia Greenlees, Koustubh Ranade, Philip M. Hemken, T. Scott Manetz, Maria J. Datwyler, Nicolette M. Jeanblanc, Katie Streicher, Partha S. Chowdhury, Rozanne Lee
Publikováno v:
Clinica chimica acta; international journal of clinical chemistry. 464
Periostin is being investigated as a potential biomarker for T-helper-2 (Th2)-driven asthma or eosinophilic inflammation and may help to identify patients more likely to benefit from interleukin-13-targeted treatments. We report the development and a
Publikováno v:
Vaccine. 30:1917-1926
A recombinant botulinum vaccine (rBV A/B) is being developed to protect adults 18-55 years of age from fatal botulism caused by inhalational intoxication with botulinum neurotoxin complex (BoNT) serotype A, subtype A1 (BoNT/A1) and BoNT serotype B, s
Autor:
James Szabo, Richard Stout, Myron M. Levine, Eileen M. Barry, Karina Ramirez, Scott Manetz, Jeffrey B. Ulmer, Marcela F. Pasetti
Publikováno v:
Human Gene Therapy. 19:522-531
Measles still causes considerable morbidity and mortality among infants and young children in developing countries. To develop a new public health tool to reduce this burden, we designed two Sindbis virus replicon vaccines encoding measles virus (MV)